Rituximab Treatment to Control Epstein-Barr Virus (EBV) Infection in X-Linked Lymphoproliferative Disorder (XLP)

Rituximab Treatment to Control Epstein-Barr Virus (EBV) Infection in X-Linked Lymphoproliferative Disorder (XLP)

Despite negative SAP (signaling lymphocytic activation molecule [SLAM]-associated protein) gene mutation analysis and no history of fulminant infectious mononucleosis or lymphoma, his phenotype was characteristic of XLP. At age 8, bone marrow transplant from a matched unrelated donor was rejected wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Allergy and Clinical Immunology 2006-02, Vol.117 (2), p.S106-S106
Hauptverfasser: Mark, B.J., Knutsen, A.P.
Format: Artikel
Sprache:eng
Schlagworte:
Bone marrow
Cell growth
Epstein-Barr virus
Lymphoma
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Despite negative SAP (signaling lymphocytic activation molecule [SLAM]-associated protein) gene mutation analysis and no history of fulminant infectious mononucleosis or lymphoma, his phenotype was characteristic of XLP. At age 8, bone marrow transplant from a matched unrelated donor was rejected within 4 months.
ISSN:0091-6749
1097-6825
1365-2567
DOI:10.1016/j.jaci.2005.12.424